sk&f-38393 has been researched along with Heart Failure in 10 studies
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine: A selective D1 dopamine receptor agonist used primarily as a research tool.
1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol : A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a phenyl substituent at position 1 and two hydroxy substituents at positions 7 and 8.
SKF 38393 : A racemate comprising equimolar amounts of (R)- and (S)-SKF 38393
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eighteen patients with New York Heart Association class III congestive heart failure were given single 100 mg oral doses of fenoldopam with food or fasting in a random-order single-blind crossover trial." | 9.07 | The effect of food on pharmacokinetics and pharmacodynamics of fenoldopam in class III heart failure. ( Blanchett, DG; Boyle, DA; Corder, CN; Cyronak, MJ; Green, JA; Jarvis, RC; Kasmer, RJ; Nara, A; Pospisil, R, 1991) |
| "To determine the maintenance of pharmacodynamic effects of fenoldopam mesylate, a dopamine-1 agonist, the invasive hemodynamic profiles of 33 patients with New York Heart Association functional class III to IV congestive heart failure were examined." | 7.68 | Assessment of hemodynamic tolerance from a 24-hour intravenous infusion of fenoldopam mesylate in congestive heart failure. ( Benotti, JR; Green, JA; Jarvis, RC; Kasmer, RJ; McCue, JE; Munger, MA; Nara, AR; Pospisil, RA, 1990) |
| "The potential interaction between fenoldopam, a DA1 selective agonist, and digoxin has been studied in 10 patients with heart failure (NYHA Class II or III) on chronic digoxin treatment." | 7.67 | Interaction study of fenoldopam--digoxin in congestive heart failure. ( Ambrosioni, E; Fuccella, LM; Malini, PL; Pasinelli, F; Riva, E; Strocchi, E; Tartagni, F; Valtancoli, G, 1989) |
| " A daily levodopa dosage of at least 4 g appears to a prerequisite for long-term response to the drug." | 6.38 | Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure. ( Hasenfuss, G; Just, H, 1989) |
| "Eighteen patients with New York Heart Association class III congestive heart failure were given single 100 mg oral doses of fenoldopam with food or fasting in a random-order single-blind crossover trial." | 5.07 | The effect of food on pharmacokinetics and pharmacodynamics of fenoldopam in class III heart failure. ( Blanchett, DG; Boyle, DA; Corder, CN; Cyronak, MJ; Green, JA; Jarvis, RC; Kasmer, RJ; Nara, A; Pospisil, R, 1991) |
| "The effects of chronic oral fenoldopam in the treatment of NYHA grade II-III heart failure secondary to ischaemic heart disease, were studied in a placebo controlled, double blind, randomised, parallel group fashion in 20 patients." | 5.06 | A preliminary study of the dopamine DA1 agonist fenoldopam in the treatment of chronic left ventricular failure due to ischaemic heart disease. ( Jeffrey, RF; Lee, MR; MacDonald, TM; Muir, AL, 1990) |
| " The novel DA1 receptor agonist fenoldopam is claiming a role in the management of hypertension, heart failure, and the preservation of renal function." | 4.78 | Dopamine and dopamine receptor agonists in cardiovascular therapy. ( Elliott, WJ; Murphy, MB, 1990) |
| "To determine the maintenance of pharmacodynamic effects of fenoldopam mesylate, a dopamine-1 agonist, the invasive hemodynamic profiles of 33 patients with New York Heart Association functional class III to IV congestive heart failure were examined." | 3.68 | Assessment of hemodynamic tolerance from a 24-hour intravenous infusion of fenoldopam mesylate in congestive heart failure. ( Benotti, JR; Green, JA; Jarvis, RC; Kasmer, RJ; McCue, JE; Munger, MA; Nara, AR; Pospisil, RA, 1990) |
| "The potential interaction between fenoldopam, a DA1 selective agonist, and digoxin has been studied in 10 patients with heart failure (NYHA Class II or III) on chronic digoxin treatment." | 3.67 | Interaction study of fenoldopam--digoxin in congestive heart failure. ( Ambrosioni, E; Fuccella, LM; Malini, PL; Pasinelli, F; Riva, E; Strocchi, E; Tartagni, F; Valtancoli, G, 1989) |
| " A daily levodopa dosage of at least 4 g appears to a prerequisite for long-term response to the drug." | 2.38 | Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure. ( Hasenfuss, G; Just, H, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 8 (80.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Patel, JJ | 1 |
| Mitha, AS | 1 |
| Sareli, P | 1 |
| de Vaal, JB | 1 |
| Blanchett, DG | 1 |
| Green, JA | 2 |
| Nara, A | 1 |
| Pospisil, R | 1 |
| Jarvis, RC | 2 |
| Kasmer, RJ | 2 |
| Boyle, DA | 1 |
| Cyronak, MJ | 1 |
| Corder, CN | 1 |
| Girbes, AR | 1 |
| van Veldhuisen, DJ | 1 |
| Smit, AJ | 1 |
| Murphy, MB | 1 |
| Elliott, WJ | 1 |
| Munger, MA | 1 |
| Benotti, JR | 1 |
| Nara, AR | 1 |
| McCue, JE | 1 |
| Pospisil, RA | 1 |
| MacDonald, TM | 1 |
| Jeffrey, RF | 1 |
| Muir, AL | 1 |
| Lee, MR | 1 |
| Holcslaw, TL | 1 |
| Beck, TR | 1 |
| Casagrande, C | 1 |
| Merlo, L | 1 |
| La Regina, A | 1 |
| Hasenfuss, G | 1 |
| Just, H | 1 |
| Strocchi, E | 1 |
| Tartagni, F | 1 |
| Malini, PL | 1 |
| Valtancoli, G | 1 |
| Ambrosioni, E | 1 |
| Pasinelli, F | 1 |
| Riva, E | 1 |
| Fuccella, LM | 1 |
4 reviews available for sk&f-38393 and Heart Failure
| Article | Year |
|---|---|
Dopamine and dopamine receptor agonists in cardiovascular therapy.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Biological Availability; Blood Pressure; | 1990 |
Clinical experience with intravenous fenoldopam.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Cardiovascular System; Chemical Phenomen | 1990 |
Development of dopaminergic drugs for the chronic treatment of congestive heart failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Deoxyepinephrine; Dopamine; Dop | 1990 |
Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Administration, Oral; Chronic Disease; D | 1989 |
3 trials available for sk&f-38393 and Heart Failure
| Article | Year |
|---|---|
Intravenous fenoldopam infusion in severe heart failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adult; Diuretics; Dopamine Agents; Dose- | 1993 |
The effect of food on pharmacokinetics and pharmacodynamics of fenoldopam in class III heart failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Administration, Oral; Adult; Aged; Biolo | 1991 |
A preliminary study of the dopamine DA1 agonist fenoldopam in the treatment of chronic left ventricular failure due to ischaemic heart disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Aged; Body Weight; Coronary Disease; Dop | 1990 |
3 other studies available for sk&f-38393 and Heart Failure
| Article | Year |
|---|---|
Dopamine agonists, a new perspective in cardiovascular therapy?
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Deoxyepinephrine; Dopamine Agents; Fenol | 1991 |
Assessment of hemodynamic tolerance from a 24-hour intravenous infusion of fenoldopam mesylate in congestive heart failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adult; Aged; Aged, 80 and over; Drug Tol | 1990 |
Interaction study of fenoldopam--digoxin in congestive heart failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adult; Aged; Digoxin; Dopamine Agents; D | 1989 |